

Box 1: Important Clinical Considerations With Either TDF/FTC or TAF/FTC as Initial ART [a]

If the patient is at risk for chronic kidney disease (e.g., age >40 years, with hypertension, diabetes, or preexisting mild kidney disease): The greater possibility of kidney disease among individuals who have risk factors is an essential component of the risk-benefit discussion and shared decision-making regarding initiation of tenofovir-containing regimens.

- Higher rates of renal dysfunction have been reported in individuals taking TDF in conjunction with RTV- and COBI-containing regimens [Pilkington, et al. 2020; Hill, et al. 2018; Cuzin, et al. 2017; Ryom, et al. 2013; Goicoechea, et al. 2008].
- For people at low risk for kidney disease, TDF, when not combined with a regimen that contains a pharmacokinetic booster (RTV or COBI), appears to have similar renal safety to TAF [Pilkington, et al. 2020; Hill, et al. 2018].
- TAF has fewer adverse effects on renal function and is associated with lower rates of proteinuria than TDF [Mills(a), et al. 2016; Pozniak, et al. 2016; Sax, et al. 2015].
- TDF/FTC should be initiated only in individuals with CrCl \geq 50 mL/min.
- TAF/FTC should be initiated only in individuals with CrCl \geq 30 mL/min.

If the patient has osteopenia, osteomalacia, or osteoporosis:

- The risk of bone loss in individuals with preexisting risk factors or documented osteopenia, osteomalacia, or osteoporosis is an important component of the risk-benefit discussion and shared decision-making regarding initiation of TDF/FTC or TAF/FTC.
- TDF is associated with osteomalacia and decreases in bone mineral density [McComsey, et al. 2011; Stellbrink, et al. 2010; Perrot, et al. 2009].
- TAF/FTC is preferred for people with osteoporosis.

If the patient has concerns about weight gain, hyperlipidemia, or metabolic disorders:

- Greater weight gain has been observed with initiation of TAF than TDF and with a switch from TDF to TAF, especially in conjunction with INSTIs [Łomiak, et al. 2021; Surial, et al. 2021; Bourgi(a), et al. 2020; Bourgi(b), et al. 2020; Calmy, et al. 2020; Lake, et al. 2020; Sax, et al. 2020; Venter, et al. 2020; Venter, et al. 2019].
- TDF is associated with lower lipid levels than TAF [Souza, et al. 2013].

If the patient is an adolescent or youth: There is limited data on bone safety in adolescents taking TAF/FTC. However, given the more favorable bone biomarkers of TAF versus TDF, TAF may have an advantage in adolescents who have not achieved bone maturation. Because this advantage is theoretical and not currently supported with clinical data, a clear recommendation cannot be made at this time.

If the patient is pregnant or attempting to conceive:

- Information about the potential benefits and risks of taking tenofovir-containing regimens during pregnancy is an essential component of shared decision-making regarding risk reduction.
- Due to the greater experience with TDF in this population, TDF/FTC is the preferred dual NRTI backbone for use as HIV treatment during pregnancy [b].
- Prospectively report information regarding the use of ART medications during pregnancy to the [Antiretroviral Pregnancy Registry](#).

If the patient has active chronic HBV:

- TDF, TAF, and FTC are active against HBV. TDF and TAF are considered equally effective against HBV [c].
- Discontinuation of TDF/FTC or TAF/FTC in patients with chronic HBV requires close monitoring for rebound HBV viremia.

Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; COBI, cobicistat; CrCl, creatinine clearance; DHHS, U.S. Department of Health and Human Services; FDA, U.S. Food and Drug Administration; FTC, emtricitabine; HBV, hepatitis B virus; INSTI, integrase strand transfer inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

Notes:

- Consider safety, cost, and access when choosing between use of TDF/FTC or TAF/FTC.
- Refer to DHHS [Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States](#).
- TDF and TAF are approved by the FDA as treatment for HBV. FTC is also active against HBV but is not FDA-approved for HBV treatment. TDF or TAF in combination with FTC or 3TC, which is FDA-approved for HBV treatment and is molecularly similar to FTC, is commonly used in patients with HIV/HBV coinfection as part of an antiretroviral regimen to treat both infections.

References

Bourgi(a) K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naïve persons starting dolutegravir-based antiretroviral therapy. *Clin Infect Dis* 2020;70(7):1267–74. [PMID: 31100116] <https://pubmed.ncbi.nlm.nih.gov/31100116>

Bourgi(b) K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. *J Int AIDS Soc* 2020;23(4):e25484. [PMID: 32294337] <https://pubmed.ncbi.nlm.nih.gov/32294337>

Calmy A, Tovar Sanchez T, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. *Lancet HIV* 2020;7(10):e677–87. [PMID: 33010241] <https://pubmed.ncbi.nlm.nih.gov/33010241>

Cuzin L, Pugliese P, Allavena C, et al. Antiretroviral therapy as a risk factor for chronic kidney disease: results from traditional regression modeling and causal approach in a large observational study. *PLoS One* 2017;12(12):e0187517. [PMID: 29216208] <https://pubmed.ncbi.nlm.nih.gov/29216208>

Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. *J Infect Dis* 2008;197(1):102–8. [PMID: 18171292] <https://pubmed.ncbi.nlm.nih.gov/18171292>

Hill A, Hughes SL, Gotham D, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? *J Virus Erad* 2018;4(2):72–79. [PMID: 29682298] <https://pubmed.ncbi.nlm.nih.gov/29682298>

Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. *Clin Infect Dis* 2020;71(9):e471–77. [PMID: 32099991] <https://pubmed.ncbi.nlm.nih.gov/32099991>

Łomiak M, Stępnicki J, Mikuła T, et al. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group. *Int J STD AIDS* 2021;32(6):570–77. [PMID: 33612018] <https://pubmed.ncbi.nlm.nih.gov/33612018>

McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. *J Infect Dis* 2011;203(12):1791–1801. [PMID: 21606537] <https://pubmed.ncbi.nlm.nih.gov/21606537>

Mills(a) A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis* 2016;16(1):43–52. [PMID: 26538525] <https://pubmed.ncbi.nlm.nih.gov/26538525>

Perrot S, Aslangul E, Szwebel T, et al. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. *J Clin Rheumatol* 2009;15(2):72–74. [PMID: 19265350] <https://pubmed.ncbi.nlm.nih.gov/19265350>

Pilkington V, Hughes SL, Pepperrell T, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. *AIDS* 2020;34(15):2259–68. [PMID: 33048869] <https://pubmed.ncbi.nlm.nih.gov/33048869>

Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. *J Acquir Immune Defic Syndr* 2016;71(5):530–37. [PMID: 26627107] <https://pubmed.ncbi.nlm.nih.gov/26627107>

Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. *J Infect Dis* 2013;207(9):1359–69. [PMID: 23382571] <https://pubmed.ncbi.nlm.nih.gov/23382571>

Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. *Clin Infect Dis* 2020;71(6):1379–89. [PMID: 31606734] <https://pubmed.ncbi.nlm.nih.gov/31606734>

Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet* 2015;385(9987):2606–15. [PMID: 25890673] <https://pubmed.ncbi.nlm.nih.gov/25890673>

Souza SJ, Luzia LA, Santos SS, et al. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. *Rev Assoc Med Bras (1992)* 2013;59(2):186–98. [PMID: 23582562] <https://pubmed.ncbi.nlm.nih.gov/23582562>

Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. *Clin Infect Dis* 2010;51(8):963–72. [PMID: 20828304] <https://pubmed.ncbi.nlm.nih.gov/20828304>

Surial B, Mugglin C, Calmy A, et al. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. *Ann Intern Med* 2021;174(6):758–67. [PMID: 33721521] <https://pubmed.ncbi.nlm.nih.gov/33721521>

Venter WD, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med* 2019;381(9):803–15. [PMID: 31339677] <https://pubmed.ncbi.nlm.nih.gov/31339677>

Venter WD, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV* 2020;7(10):e666–76. [PMID: 33010240] <https://pubmed.ncbi.nlm.nih.gov/33010240>